HAVCR2 and glioma: Notably, the expression of TIM-3 and LAG-3 immune checkpoints is relatively low in gliomas [11], and as such these therapeutic targets are unlikely to be beneficial for the treatment of patients with glioma for most patients and especially as a monotherapy.